At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RXRX Recursion Pharmaceuticals, Inc.
Trading 06-29 12:52:54 EDT
3.65
+0.13
+3.69%
High3.74Low3.55Vol16.12M
Open3.62D1 Closing3.52Amplitude5.40%
Mkt Cap1.93BTradable Cap1.51BTotal Shares527.40M
T/O59.02MT/O Rate3.88%Tradable Shares415.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cathie Wood’s ARK Investment buys 260K shares of Recursion Pharmaceuticals today
TIPRANKS  ·  06-25
Cathie Wood’s ARK Investment buys 260K shares of Recursion Pharmaceuticals today
Recursion Pharmaceuticals director Bumpus Namandje disposes of 3,963 common shares worth $12,599.34
Reuters  ·  06-23
Recursion Pharmaceuticals director Bumpus Namandje disposes of 3,963 common shares worth $12,599.34
Recursion Shareholders Reelect Directors and Approve Governance Matters
TIPRANKS  ·  06-19
Recursion Shareholders Reelect Directors and Approve Governance Matters
Recursion Pharmaceuticals holds annual shareholder meeting
Reuters  ·  06-19
Recursion Pharmaceuticals holds annual shareholder meeting
Nvidia-Related Stocks Rally. Applied Digital Up 11%; WhiteFiber And Nebius Up 5%; Nano-X And Arm Up 4%; CoreWeave, Serve Robotics And Lumentum Up 3%
Tiger Newspress  ·  06-09
Nvidia-Related Stocks Rally. Applied Digital Up 11%; WhiteFiber And Nebius Up 5%; Nano-X And Arm Up 4%; CoreWeave, Serve Robotics And Lumentum Up 3%
Recursion Pharma director Christopher Gibson disposes of 40,000 common shares for $144,800
Reuters  ·  06-06
Recursion Pharma director Christopher Gibson disposes of 40,000 common shares for $144,800
Recursion CEO and President Najat Khan sells 23,588 shares worth $84,459
Reuters  ·  06-06
Recursion CEO and President Najat Khan sells 23,588 shares worth $84,459
Recursion Pharma director Bumpus Namandje disposes of 4,386 common shares for $15,526.44
Reuters  ·  06-05
Recursion Pharma director Bumpus Namandje disposes of 4,386 common shares for $15,526.44
Recursion Pharma director Blake Borgeson disposes of 30,000 shares worth $110,400
Reuters  ·  06-05
Recursion Pharma director Blake Borgeson disposes of 30,000 shares worth $110,400
Recursion to Present at Goldman Sachs Global Healthcare Conference
Reuters  ·  06-02
Recursion to Present at Goldman Sachs Global Healthcare Conference
Recursion to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  06-02
Recursion to Participate in Upcoming Investor Conferences
Recursion grants inducement RSUs covering 2,991,840 shares to 33 new hires
Reuters  ·  05-30
Recursion grants inducement RSUs covering 2,991,840 shares to 33 new hires
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
THOMSON REUTERS  ·  05-30
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Recursion Pharmaceuticals director Christopher Gibson disposes of 40,000 common shares for $ 123,200
Reuters  ·  05-28
Recursion Pharmaceuticals director Christopher Gibson disposes of 40,000 common shares for $ 123,200
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Shares Lose Momentum In Recent Months
Simply Wall St.  ·  05-24
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Shares Lose Momentum In Recent Months
Nvidia-Linked Shares Rally. Applied Digital up 18%; NEBIUS up 17%; WhiteFiber up 13%; ARM Holdings, Lumentum up 9% Each; CoreWeave up Nearly 5%
Tiger Newspress  ·  05-21
Nvidia-Linked Shares Rally. Applied Digital up 18%; NEBIUS up 17%; WhiteFiber up 13%; ARM Holdings, Lumentum up 9% Each; CoreWeave up Nearly 5%
Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones  ·  05-15
Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Stock Track | Recursion Pharmaceuticals Soars 5.08% Intraday After Morgan Stanley Raises Price Target
Stock Track  ·  05-14
Stock Track | Recursion Pharmaceuticals Soars 5.08% Intraday After Morgan Stanley Raises Price Target
Morgan Stanley Raises Price Target on Recursion Pharmaceuticals to $5.50 From $5, Keeps Equalweight Rating
MT Newswires Live  ·  05-14
Morgan Stanley Raises Price Target on Recursion Pharmaceuticals to $5.50 From $5, Keeps Equalweight Rating
Recursion director Christopher Gibson disposes of 60,000 shares for $134,800
Reuters  ·  05-09
Recursion director Christopher Gibson disposes of 60,000 shares for $134,800

Introduction

Company Name.
Recursion Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Issue price:
--